SYN-AKE
A synthetic snake-venom-mimetic tripeptide marketed as a topical, reversible "botulinum-like" wrinkle relaxer.
SYN-AKE (Dipeptide Diaminobutyroyl Benzylamide Diacetate; also referenced as Tripeptide-3) is a synthetic peptide cosmetic ingredient engineered to mimic waglerin-1, a neurotoxic peptide found in the venom of Wagler's pit viper (Tropidolaemus wagleri). It is formulated into topical anti-aging products with the claim that it softens dynamic expression lines by reversibly antagonizing muscle-type nicotinic acetylcholine receptors (nAChR) at facial neuromuscular junctions. The mechanism is pharmacologically plausible given waglerin-1's known nAChR antagonism, but there are no published peer-reviewed in vivo human or animal efficacy studies indexed for the ingredient itself.
Class
Synthetic peptide (waglerin-1 mimetic) cosmetic active ingredient
Routes
Topical
Category
Skin, Hair & Cosmetic
Researched benefits
What it's studied for
Dynamic wrinkle reduction
Marketed to reduce the appearance of dynamic wrinkles (expression lines) by attenuating the muscle microcontractions that drive them. This claim rests on the peptide's proposed nAChR antagonism rather than on published in vivo human efficacy data.
Expression line softening
Positioned as a topical way to soften lines such as forehead and crow's-feet creases, functioning as a needle-free analog to injectable neuromuscular relaxers.
Muscle relaxation at the neuromuscular junction
Proposed to reduce motor signal transmission to facial expression muscles by reversibly blocking postsynaptic nicotinic receptors, producing a localized, temporary relaxing effect.
General anti-aging positioning
Included in anti-aging formulations aimed at a smoother, more youthful facial appearance; effects are cosmetic and reversible rather than structural.
Mechanism
How it works
SYN-AKE is designed to mimic waglerin-1, a neurotoxic peptide from the venom of Wagler's pit viper. Waglerin-1 is an established antagonist of the muscle-type nicotinic acetylcholine receptor (nAChR). By emulating this activity, SYN-AKE is proposed to competitively bind nAChRs at neuromuscular junctions in facial skin.
By antagonizing the postsynaptic nicotinic receptor, the peptide is theorized to reduce transmission of the motor signal that triggers muscle contraction. Fewer or weaker involuntary microcontractions in facial expression muscles would, in principle, lessen the repeated folding of skin that produces dynamic lines. The intended effect is topical, localized to the area of application, and fully reversible.
This makes SYN-AKE conceptually analogous to a topically applied, reversible botulinum-toxin mimic. Importantly, the mechanism is pharmacologically plausible at the molecular level but has not been validated by independent in vivo human or animal studies in the indexed scientific literature; indexed evidence is limited to in silico and in vitro work rather than clinical efficacy or pharmacokinetic data.
Safety
Side effects & considerations
Contraindications & cautions
- Pregnant or nursing (consult a qualified healthcare professional first)
SYN-AKE is generally considered lower risk in research/cosmetic contexts. The only reported consideration in the source is caution during pregnancy or nursing. Individual response varies, and no controlled human safety studies for the ingredient are indexed.
FAQ
SYN-AKE — common questions
What is SYN-AKE?
SYN-AKE (Dipeptide Diaminobutyroyl Benzylamide Diacetate, also called Tripeptide-3) is a synthetic peptide designed to mimic waglerin-1, a neurotoxic component of Wagler's pit viper venom. It is formulated as a topical cosmetic active claimed to reduce dynamic wrinkles by antagonizing muscle nicotinic acetylcholine receptors at facial neuromuscular junctions, acting like a reversible, topically applied botulinum-toxin mimic.
What is SYN-AKE primarily studied for?
It is primarily discussed for wrinkle reduction, expression line softening, muscle relaxation, and general anti-aging.
How is SYN-AKE thought to work?
It is proposed to competitively antagonize the muscle-type nicotinic acetylcholine receptor, reducing the motor signal to facial expression muscles and thereby lessening the microcontractions that create dynamic lines. The effect is described as topical, localized, and fully reversible.
Is there clinical evidence that SYN-AKE works?
No published peer-reviewed in vivo human studies, controlled animal efficacy studies, or pharmacokinetic data for SYN-AKE are indexed in PubMed. Available indexed literature is limited to in silico and in vitro work, so the anti-wrinkle claim rests on a plausible mechanism and supplier testing rather than independent clinical evidence.
Is SYN-AKE FDA approved?
No. SYN-AKE has no FDA approval and no regulatory drug status in any jurisdiction. It is marketed as a cosmetic ingredient, and its availability is classified as research only.
What are the side effects of SYN-AKE?
It is generally considered lower risk. The main reported consideration is caution if pregnant or nursing. Consult a qualified healthcare professional before use, as individual response varies.
